CN109481510A - 一种有助于改善2型糖尿病及其并发症的合生元复方制剂及其制备方法 - Google Patents
一种有助于改善2型糖尿病及其并发症的合生元复方制剂及其制备方法 Download PDFInfo
- Publication number
- CN109481510A CN109481510A CN201811181371.9A CN201811181371A CN109481510A CN 109481510 A CN109481510 A CN 109481510A CN 201811181371 A CN201811181371 A CN 201811181371A CN 109481510 A CN109481510 A CN 109481510A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- synbiotic
- preparation
- bifidobacterium
- compound preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 58
- 150000001875 compounds Chemical class 0.000 title claims abstract description 37
- 235000019722 synbiotics Nutrition 0.000 title claims abstract description 35
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 32
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 39
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 39
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 39
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 39
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 38
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 38
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 38
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 35
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 35
- 241000186606 Lactobacillus gasseri Species 0.000 claims abstract description 27
- 239000006041 probiotic Substances 0.000 claims abstract description 24
- 235000018291 probiotics Nutrition 0.000 claims abstract description 24
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims abstract description 21
- 229920002581 Glucomannan Polymers 0.000 claims abstract description 21
- 229920001202 Inulin Polymers 0.000 claims abstract description 21
- 229940046240 glucomannan Drugs 0.000 claims abstract description 21
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 21
- 229940029339 inulin Drugs 0.000 claims abstract description 21
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 20
- 229920001503 Glucan Polymers 0.000 claims abstract description 17
- 238000004108 freeze drying Methods 0.000 claims abstract description 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 238000012856 packing Methods 0.000 claims abstract description 7
- 230000000529 probiotic effect Effects 0.000 claims abstract description 7
- 238000000855 fermentation Methods 0.000 claims description 18
- 230000004151 fermentation Effects 0.000 claims description 18
- -1 hydroxypropyl methyl Chemical group 0.000 claims description 15
- 235000013406 prebiotics Nutrition 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- 244000005700 microbiome Species 0.000 claims description 9
- 235000013325 dietary fiber Nutrition 0.000 claims description 8
- 101001076687 Lactobacillus gasseri Inulosucrase Proteins 0.000 claims description 7
- 235000013361 beverage Nutrition 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 230000005180 public health Effects 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 6
- 235000020183 skimmed milk Nutrition 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 5
- 229940039696 lactobacillus Drugs 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 2
- 239000000835 fiber Substances 0.000 claims 2
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 claims 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 3
- 230000036772 blood pressure Effects 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 230000036542 oxidative stress Effects 0.000 abstract description 2
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 101500016420 Oncorhynchus mykiss Glucagon-like peptide 1-1 Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000020138 yakult Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种有助于改善2型糖尿病及其并发症的合生元复方制剂,该合生元复方制剂的配方包括以下组份:动物双歧杆菌乳亚种5%‑10%、两歧双歧杆菌6%‑9%、嗜酸乳杆菌8%‑12%、罗伊氏乳杆菌2%‑6%、格氏乳杆菌3%‑8%、菊粉2%‑6%、低聚果糖4%‑8%、低聚木糖8%‑11%、b葡聚糖5%‑9%、葡甘聚糖8%‑11%、羟丙基甲基纤维素2%‑4%、圆苞车前子壳粉3%‑6%,本发明还公开了一种有助于改善2型糖尿病及其并发症的合生元复方制剂的制备方法,该制备方法包括以下步骤:益生菌培养,益生菌发酵,冷冻干燥,混匀分装;本复方制剂对胰岛素抵抗、血糖血脂等生化指标及氧化应激具有改善作用,并对现行治疗方案有明显辅助治疗效果且没有明显副作用。
Description
技术领域
本发明涉及合生元复方制剂制备技术领域,具体为一种有助于改善2型糖尿病及其并发症的合生元复方制剂及其制备方法。
背景技术
糖尿病是一类以高血糖为特征的代谢性疾病。高血糖则是由于胰岛素分泌缺陷或其生物作用受损,或两者兼有引起。糖尿病患者长期存在的高血糖,会导致各种组织,特别是眼、肾、心脏、血管、神经系统的慢性损害及功能障碍等。其中,2型糖尿病又叫成人发病型糖尿病,多在35-40岁之后发病,占糖尿病患者90%以上。2型糖尿病患者体内产生胰岛素的能力并非完全丧失,但由于各种原因使胰岛素促进葡萄糖摄取和利用的效率下降,产生胰岛素抵抗,机体代偿性的分泌过多胰岛素而产生高胰岛素血症。
科研结果表明,2型糖尿病人群的肠道菌群构成与健康人群存在很大差异,主要是一些产短链脂肪酸细菌的缺失。益生菌是一类对宿主有益的活性微生物,是定植于人体肠道、生殖系统内,能产生确切健康功效从而改善宿主微生态平衡、发挥有益作用的活性有益微生物的总称。而益生元是一类安全的天然来源的食物成分,能促进益生菌的定植与增殖。在动物和临床研究中,多种益生菌、益生元及膳食纤维的单独使用或联合使用能不同程度地缓解甚至治疗2型糖尿病及其并发症,表现出极强的保健功能。其中部分益生菌则明确属于我国卫生部制定的可用于食品的微生物名录,具有较高的安全性。这些益生菌可以在肠道环境中发酵益生元及膳食纤维产生短链脂肪酸,进而刺激肠道L细胞分泌胰高血糖素样肽GLP-1,继而刺激胰岛b细胞分泌胰岛素,从而达到调节血糖的目的。另外,即使对于非糖尿病的普通人群,益生菌与益生元也能够起到促进肠道健康的良好作用,调节血脂,缓解氧化应激,并已经被应用于日常的饮料中例如养乐多等。
然而,益生菌与益生元的单一使用于各自发挥功能的机制不同,即便完全相同的益生菌/益生元对于不同的遗传背景与生活习惯的人群都会表现出很大的差别。目前已有产品的有效成分多是单一菌种或单一益生元,使得合生元复方制剂无法适应较广的人群;为此,本发明提出一种有助于改善2型糖尿病及其并发症的合生元复方制剂及其制备方法。
发明内容
本发明的目的在于提供一种有助于改善2型糖尿病及其并发症的合生元复方制剂及其制备方法,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:一种有助于改善2型糖尿病及其并发症的合生元复方制剂,该改进型合生元复方制剂的配方包括以下组份:动物双歧杆菌乳亚种5%-10%、两歧双歧杆菌6%-9%、嗜酸乳杆菌8%-12%、罗伊氏乳杆菌2%-6%、格氏乳杆菌3%-8%、菊粉2%-6%、低聚果糖4%-8%、低聚木糖8%-11%、b葡聚糖5%-9%、葡甘聚糖8%-11%、羟丙基甲基纤维素2%-4%、圆苞车前子壳粉3%-6%。
优选的,包括动物双歧杆菌乳亚种5%、两歧双歧杆菌6%、嗜酸乳杆菌8%、罗伊氏乳杆菌2%、格氏乳杆菌3%、菊粉2%、低聚果糖4%、低聚木糖8%、b葡聚糖5%、葡甘聚糖8%、羟丙基甲基纤维素2%、圆苞车前子壳粉3%。
优选的,包括动物双歧杆菌乳亚种6%、两歧双歧杆菌7%、嗜酸乳杆菌9%、罗伊氏乳杆菌3%、格氏乳杆菌4%、菊粉3%、低聚果糖5%、低聚木糖9%、b葡聚糖6%、葡甘聚糖9%、羟丙基甲基纤维素3%、圆苞车前子壳粉3%。
优选的,包括动物双歧杆菌乳亚种7%、两歧双歧杆菌8%、嗜酸乳杆菌10%、罗伊氏乳杆菌4%、格氏乳杆菌5%、菊粉4%、低聚果糖6%、低聚木糖10%、b葡聚糖7%、葡甘聚糖10%、羟丙基甲基纤维素4%、圆苞车前子壳粉5%。
优选的,包括动物双歧杆菌乳亚种8%、两歧双歧杆菌9%、嗜酸乳杆菌11%、罗伊氏乳杆菌5%、格氏乳杆菌6%、菊粉5%、低聚果糖7%、低聚木糖11%、b葡聚糖8%、葡甘聚糖11%、羟丙基甲基纤维素4%、圆苞车前子壳粉6%。
优选的,所述动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌均在我国卫生部发布的可用于食品的菌种名单之中。
一种如上所述的有助于改善2型糖尿病及其并发症的合生元复方制剂的制备方法,该制备方法包括以下步骤:
S1:益生菌培养,将动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌分别接种入五个独立的培养皿中进行培养与传代,后转接液体培养基,获取种子液;
S2:益生菌发酵,使用食品级微生物发酵条件对动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌种子液分别扩大发酵后,将发酵液离心洗涤,获得湿菌体;
S3:冷冻干燥,将脱脂乳加入到湿菌体中,使其重新悬浮,并使用冷冻干燥法干燥获得冻干菌粉,在-20摄氏度保存;
S4:混匀分装,将动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌5种益生菌冻干粉与菊粉、低聚果糖、低聚木糖、b葡聚糖、葡甘聚糖、羟丙基甲基纤维素以及圆苞车前子壳粉7种益生元及膳食纤维按一定比例混合并制成固体饮料,并在-20~4摄氏度储存冷链运输与销售。
与现有技术相比,本发明的有益效果是:本发明所采用的配方均为国标规定原料,且本发明制备出的合生元复方制剂各组分间的协同效应可得到较大提升,本复方制剂对胰岛素抵抗、血糖血脂等生化指标及氧化应激具有改善作用,并对现行治疗方案有明显辅助治疗效果且没有明显副作用;使之能够合理发挥各种益生菌与益生元的协同增效作用,以达到增大适用人群的目的。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例一
本发明提供一种技术方案:一种有助于改善2型糖尿病及其并发症的合生元复方制剂,该改进型合生元复方制剂的配方包括以下组份:动物双歧杆菌乳亚种5%、两歧双歧杆菌6%、嗜酸乳杆菌8%、罗伊氏乳杆菌2%、格氏乳杆菌3%、菊粉2%、低聚果糖4%、低聚木糖8%、b葡聚糖5%、葡甘聚糖8%、羟丙基甲基纤维素2%、圆苞车前子壳粉3%。
其中,动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌均在我国卫生部发布的可用于食品的菌种名单之中。
一种如上所述的有助于改善2型糖尿病及其并发症的合生元复方制剂的制备方法,该制备方法包括以下步骤:
S1:益生菌培养,将动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌分别接种入五个独立的培养皿中进行培养与传代,后转接液体培养基,获取种子液;
S2:益生菌发酵,使用食品级微生物发酵条件对动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌种子液分别扩大发酵后,将发酵液离心洗涤,获得湿菌体;
S3:冷冻干燥,将脱脂乳加入到湿菌体中,使其重新悬浮,并使用冷冻干燥法干燥获得冻干菌粉,在-20摄氏度保存;
S4:混匀分装,将动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌5种益生菌冻干粉与菊粉、低聚果糖、低聚木糖、b葡聚糖、葡甘聚糖、羟丙基甲基纤维素以及圆苞车前子壳粉7种益生元及膳食纤维按一定比例混合并制成固体饮料,并在-20~4摄氏度储存冷链运输与销售。
实施例二
本发明提供一种技术方案:一种有助于改善2型糖尿病及其并发症的合生元复方制剂,该改进型合生元复方制剂的配方包括以下组份:动物双歧杆菌乳亚种6%、两歧双歧杆菌7%、嗜酸乳杆菌9%、罗伊氏乳杆菌3%、格氏乳杆菌4%、菊粉3%、低聚果糖5%、低聚木糖9%、b葡聚糖6%、葡甘聚糖9%、羟丙基甲基纤维素3%、圆苞车前子壳粉3%。
其中,动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌均在我国卫生部发布的可用于食品的菌种名单之中。
一种如上所述的有助于改善2型糖尿病及其并发症的合生元复方制剂的制备方法,该制备方法包括以下步骤:
S1:益生菌培养,将动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌分别接种入五个独立的培养皿中进行培养与传代,后转接液体培养基,获取种子液;
S2:益生菌发酵,使用食品级微生物发酵条件对动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌种子液分别扩大发酵后,将发酵液离心洗涤,获得湿菌体;
S3:冷冻干燥,将脱脂乳加入到湿菌体中,使其重新悬浮,并使用冷冻干燥法干燥获得冻干菌粉,在-20摄氏度保存;
S4:混匀分装,将动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌5种益生菌冻干粉与菊粉、低聚果糖、低聚木糖、b葡聚糖、葡甘聚糖、羟丙基甲基纤维素以及圆苞车前子壳粉7种益生元及膳食纤维按一定比例混合并制成固体饮料,并在-20~4摄氏度储存冷链运输与销售。
实施例三
本发明提供一种技术方案:一种有助于改善2型糖尿病及其并发症的合生元复方制剂,该改进型合生元复方制剂的配方包括以下组份:动物双歧杆菌乳亚种7%、两歧双歧杆菌8%、嗜酸乳杆菌10%、罗伊氏乳杆菌4%、格氏乳杆菌5%、菊粉4%、低聚果糖6%、低聚木糖10%、b葡聚糖7%、葡甘聚糖10%、羟丙基甲基纤维素4%、圆苞车前子壳粉5%。
其中,动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌均在我国卫生部发布的可用于食品的菌种名单之中。
一种如上所述的有助于改善2型糖尿病及其并发症的合生元复方制剂的制备方法,该制备方法包括以下步骤:
S1:益生菌培养,将动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌分别接种入五个独立的培养皿中进行培养与传代,后转接液体培养基,获取种子液;
S2:益生菌发酵,使用食品级微生物发酵条件对动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌种子液分别扩大发酵后,将发酵液离心洗涤,获得湿菌体;
S3:冷冻干燥,将脱脂乳加入到湿菌体中,使其重新悬浮,并使用冷冻干燥法干燥获得冻干菌粉,在-20摄氏度保存;
S4:混匀分装,将动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌5种益生菌冻干粉与菊粉、低聚果糖、低聚木糖、b葡聚糖、葡甘聚糖、羟丙基甲基纤维素以及圆苞车前子壳粉7种益生元及膳食纤维按一定比例混合并制成固体饮料,并在-20~4摄氏度储存冷链运输与销售。
实施例四
本发明提供一种技术方案:一种有助于改善2型糖尿病及其并发症的合生元复方制剂,该改进型合生元复方制剂的配方包括以下组份:动物双歧杆菌乳亚种8%、两歧双歧杆菌9%、嗜酸乳杆菌11%、罗伊氏乳杆菌5%、格氏乳杆菌6%、菊粉5%、低聚果糖7%、低聚木糖11%、b葡聚糖8%、葡甘聚糖11%、羟丙基甲基纤维素4%、圆苞车前子壳粉6%。
其中,动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌均在我国卫生部发布的可用于食品的菌种名单之中。
一种如上所述的有助于改善2型糖尿病及其并发症的合生元复方制剂的制备方法,该制备方法包括以下步骤:
S1:益生菌培养,将动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌分别接种入五个独立的培养皿中进行培养与传代,后转接液体培养基,获取种子液;
S2:益生菌发酵,使用食品级微生物发酵条件对动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌种子液分别扩大发酵后,将发酵液离心洗涤,获得湿菌体;
S3:冷冻干燥,将脱脂乳加入到湿菌体中,使其重新悬浮,并使用冷冻干燥法干燥获得冻干菌粉,在-20摄氏度保存;
S4:混匀分装,将动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌5种益生菌冻干粉与菊粉、低聚果糖、低聚木糖、b葡聚糖、葡甘聚糖、羟丙基甲基纤维素以及圆苞车前子壳粉7种益生元及膳食纤维按一定比例混合并制成固体饮料,并在-20~4摄氏度储存冷链运输与销售。
通过对四组实施例进行成分检测,并且从市场上挑选了一组合生元复方制剂进行对比,检测结果如下:
从上表的实验数据可知,本方案的第四组合生元复方制剂够合理发挥各种益生菌与益生元的协同增效作用,以达到增大适用人群的目的,因此具有较好的推广价值。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (7)
1.一种有助于改善2型糖尿病及其并发症的合生元复方制剂,其特征在于;该改进型合生元复方制剂的配方包括以下组份:动物双歧杆菌乳亚种5%-10%、两歧双歧杆菌6%-9%、嗜酸乳杆菌8%-12%、罗伊氏乳杆菌2%-6%、格氏乳杆菌3%-8%、菊粉2%-6%、低聚果糖4%-8%、低聚木糖8%-11%、b葡聚糖5%-9%、葡甘聚糖8%-11%、羟丙基甲基纤维素2%-4%、圆苞车前子壳粉3%-6%。
2.根据权利要求1所述的一种有助于改善2型糖尿病及其并发症的合生元复方制剂,其特征在于:包括动物双歧杆菌乳亚种5%、两歧双歧杆菌6%、嗜酸乳杆菌8%、罗伊氏乳杆菌2%、格氏乳杆菌3%、菊粉2%、低聚果糖4%、低聚木糖8%、b葡聚糖5%、葡甘聚糖8%、羟丙基甲基纤维素2%、圆苞车前子壳粉3%。
3.根据权利要求1所述的一种有助于改善2型糖尿病及其并发症的合生元复方制剂,其特征在于:包括动物双歧杆菌乳亚种6%、两歧双歧杆菌7%、嗜酸乳杆菌9%、罗伊氏乳杆菌3%、格氏乳杆菌4%、菊粉3%、低聚果糖5%、低聚木糖9%、b葡聚糖6%、葡甘聚糖9%、羟丙基甲基纤维素3%、圆苞车前子壳粉3%。
4.根据权利要求1所述的一种有助于改善2型糖尿病及其并发症的合生元复方制剂,其特征在于:包括动物双歧杆菌乳亚种7%、两歧双歧杆菌8%、嗜酸乳杆菌10%、罗伊氏乳杆菌4%、格氏乳杆菌5%、菊粉4%、低聚果糖6%、低聚木糖10%、b葡聚糖7%、葡甘聚糖10%、羟丙基甲基纤维素4%、圆苞车前子壳粉5%。
5.根据权利要求1所述的一种有助于改善2型糖尿病及其并发症的合生元复方制剂,其特征在于:包括动物双歧杆菌乳亚种8%、两歧双歧杆菌9%、嗜酸乳杆菌11%、罗伊氏乳杆菌5%、格氏乳杆菌6%、菊粉5%、低聚果糖7%、低聚木糖11%、b葡聚糖8%、葡甘聚糖11%、羟丙基甲基纤维素4%、圆苞车前子壳粉6%。
6.根据权利要求1所述的一种有助于改善2型糖尿病及其并发症的合生元复方制剂,其特征在于:所述动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌均在我国卫生部发布的可用于食品的菌种名单之中。
7.一种如权利要求1-6任意一条所述的有助于改善2型糖尿病及其并发症的合生元复方制剂的制备方法,其特征在于:该制备方法包括以下步骤:
S1:益生菌培养,将动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌分别接种入五个独立的培养皿中进行培养与传代,后转接液体培养基,获取种子液;
S2:益生菌发酵,使用食品级微生物发酵条件对动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌种子液分别扩大发酵后,将发酵液离心洗涤,获得湿菌体;
S3:冷冻干燥,将脱脂乳加入到湿菌体中,使其重新悬浮,并使用冷冻干燥法干燥获得冻干菌粉,在-20摄氏度保存;
S4:混匀分装,将动物双歧杆菌乳亚种、两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌以及格氏乳杆菌5种益生菌冻干粉与菊粉、低聚果糖、低聚木糖、b葡聚糖、葡甘聚糖、羟丙基甲基纤维素以及圆苞车前子壳粉7种益生元及膳食纤维按一定比例混合并制成固体饮料,并在-20~4摄氏度储存冷链运输与销售。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811181371.9A CN109481510A (zh) | 2018-10-11 | 2018-10-11 | 一种有助于改善2型糖尿病及其并发症的合生元复方制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811181371.9A CN109481510A (zh) | 2018-10-11 | 2018-10-11 | 一种有助于改善2型糖尿病及其并发症的合生元复方制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109481510A true CN109481510A (zh) | 2019-03-19 |
Family
ID=65690211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811181371.9A Pending CN109481510A (zh) | 2018-10-11 | 2018-10-11 | 一种有助于改善2型糖尿病及其并发症的合生元复方制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109481510A (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110150669A (zh) * | 2019-04-29 | 2019-08-23 | 河北一然生物科技有限公司 | 一种适于糖尿病患者食用的益生菌组合物及其应用 |
CN111084385A (zh) * | 2019-04-18 | 2020-05-01 | 广东省微生物研究所(广东省微生物分析检测中心) | 一种具有降血糖功效的益生菌制剂的功能性食品 |
CN112293731A (zh) * | 2020-10-30 | 2021-02-02 | 阎飞 | 一种提升益生菌在肠道内成活率和定植率的方法 |
CN113197288A (zh) * | 2020-08-31 | 2021-08-03 | 内蒙古蒙牛乳业(集团)股份有限公司 | 改善糖耐量和甘油三脂水平的益生菌组合物及制备方法 |
CN113197313A (zh) * | 2020-09-02 | 2021-08-03 | 内蒙古蒙牛乳业(集团)股份有限公司 | 具有改善胰岛素抵抗及空腹血糖的益生菌组合物及制备方法 |
CN113768023A (zh) * | 2021-08-31 | 2021-12-10 | 无棣珍康生物科技有限公司 | 一种可以抵抗细胞老化的有益食品 |
CN113841774A (zh) * | 2021-08-31 | 2021-12-28 | 无棣珍康生物科技有限公司 | 一种抗氧化型能清除自由基的有益食品 |
CN115948273A (zh) * | 2022-06-21 | 2023-04-11 | 合肥瀚微生物科技有限公司 | 治疗糖尿病及相关病症的两歧双歧杆菌 |
CN118415342A (zh) * | 2024-07-05 | 2024-08-02 | 浙江衡美健康科技股份有限公司 | 高效提高脂肪代谢的组合物及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105343585A (zh) * | 2015-11-03 | 2016-02-24 | 齐齐哈尔医学院 | 一种玉米须泡腾片及其制备方法 |
CN107518073A (zh) * | 2017-08-10 | 2017-12-29 | 山东阳春羊奶乳业有限公司 | 一种益生菌羊奶片及其制备方法 |
CN108295098A (zh) * | 2018-02-02 | 2018-07-20 | 云南中京国建投资有限公司 | 一种辅助降血糖的合生元组合物及其制剂与应用 |
-
2018
- 2018-10-11 CN CN201811181371.9A patent/CN109481510A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105343585A (zh) * | 2015-11-03 | 2016-02-24 | 齐齐哈尔医学院 | 一种玉米须泡腾片及其制备方法 |
CN107518073A (zh) * | 2017-08-10 | 2017-12-29 | 山东阳春羊奶乳业有限公司 | 一种益生菌羊奶片及其制备方法 |
CN108295098A (zh) * | 2018-02-02 | 2018-07-20 | 云南中京国建投资有限公司 | 一种辅助降血糖的合生元组合物及其制剂与应用 |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111084385A (zh) * | 2019-04-18 | 2020-05-01 | 广东省微生物研究所(广东省微生物分析检测中心) | 一种具有降血糖功效的益生菌制剂的功能性食品 |
CN110150669A (zh) * | 2019-04-29 | 2019-08-23 | 河北一然生物科技有限公司 | 一种适于糖尿病患者食用的益生菌组合物及其应用 |
CN113197288A (zh) * | 2020-08-31 | 2021-08-03 | 内蒙古蒙牛乳业(集团)股份有限公司 | 改善糖耐量和甘油三脂水平的益生菌组合物及制备方法 |
CN113197313A (zh) * | 2020-09-02 | 2021-08-03 | 内蒙古蒙牛乳业(集团)股份有限公司 | 具有改善胰岛素抵抗及空腹血糖的益生菌组合物及制备方法 |
CN113197313B (zh) * | 2020-09-02 | 2023-10-27 | 内蒙古蒙牛乳业(集团)股份有限公司 | 具有改善胰岛素抵抗及空腹血糖的益生菌组合物及制备方法 |
CN112293731A (zh) * | 2020-10-30 | 2021-02-02 | 阎飞 | 一种提升益生菌在肠道内成活率和定植率的方法 |
CN113768023A (zh) * | 2021-08-31 | 2021-12-10 | 无棣珍康生物科技有限公司 | 一种可以抵抗细胞老化的有益食品 |
CN113841774A (zh) * | 2021-08-31 | 2021-12-28 | 无棣珍康生物科技有限公司 | 一种抗氧化型能清除自由基的有益食品 |
CN115948273A (zh) * | 2022-06-21 | 2023-04-11 | 合肥瀚微生物科技有限公司 | 治疗糖尿病及相关病症的两歧双歧杆菌 |
CN115948273B (zh) * | 2022-06-21 | 2023-07-18 | 合肥瀚微生物科技有限公司 | 治疗糖尿病及相关病症的两歧双歧杆菌 |
CN118415342A (zh) * | 2024-07-05 | 2024-08-02 | 浙江衡美健康科技股份有限公司 | 高效提高脂肪代谢的组合物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109481510A (zh) | 一种有助于改善2型糖尿病及其并发症的合生元复方制剂及其制备方法 | |
CN104740138A (zh) | 包含芦荟、益生菌和益生元的组合物及其用途 | |
CN100342005C (zh) | 一种活性乳酸菌制品的制备方法 | |
CN103908585B (zh) | 用于预防和治疗便秘的益生菌发酵组合物 | |
US11564955B2 (en) | Composition including, as active ingredient, strain having ability to produce formic acid for preventing or treating obesity or metabolic syndromes caused by obesity | |
TW201808315A (zh) | 胚芽乳酸桿菌用於製備改善運動表現及降低肌肉疲勞之益生菌組合物之用途 | |
CN104432001B (zh) | 可食用组合物及其用途 | |
CN110325198A (zh) | 益生菌在治疗和/或预防银屑病中的用途 | |
KR20060135016A (ko) | 유카 추출물, 퀼라야 추출물 및 유산균을 포함하는 조성물및 상기 조성물을 함유하는 음식물 | |
JP5592640B2 (ja) | 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤、その製造方法、視床下部−下垂体−副腎皮質系の活動抑制剤、及び交感神経−副腎髄質系の活動抑制剤 | |
CN109315769A (zh) | 一种用于改善人体肠内环境的组合物及其制备方法 | |
TW201705969A (zh) | 新穎馬利乳酸桿菌aps1及其用途 | |
JP6793380B2 (ja) | スクロース摂取による血糖値上昇を抑制する物質の評価方法、スクリーニング方法及び製造方法 | |
JP4540376B2 (ja) | 乳酸菌生産物質 | |
CN108795823B (zh) | 一种改善女性孕产妇肠道菌群的益生菌的培养方法和应用 | |
CN109715784A (zh) | 细菌 | |
Gupta et al. | Selection criteria for probiotics and potential of cereal based food products as novel probiotic-carriers | |
CN108968025A (zh) | 调节血糖血脂的高浓度乳酸菌冻干粉 | |
CN107927793A (zh) | 预防或减轻人体便秘的合生元制剂及其制备方法 | |
CN108523123A (zh) | 一种糖尿病全营养支持食品 | |
JPH07265064A (ja) | 腸内細菌叢改善組成物 | |
CN109965290B (zh) | 改善肠道菌群代餐粉及其应用 | |
JP6061530B2 (ja) | Nash予防治療剤 | |
CN113209141B (zh) | 一种基于褐藻提取物与罗伊氏乳杆菌的组合物及其应用 | |
CN105343132B (zh) | 治疗结肠炎的组合物、药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190417 Address after: 214135 Room 573, Swan Block D, Wuxi Software Park, 111 Linghu Avenue, Xinwu District, Wuxi City, Jiangsu Province Applicant after: Jiangsu Hongzhong Baide Biotechnology Co., Ltd. Address before: 214135 5th Floor, Southeast Courtyard, 99 Linghu Avenue, New District, Wuxi City, Jiangsu Province Applicant before: Zhang Junyi |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190319 |